Optimizing Therapy for Ovarian Cancer: Recent Data Highlights
Episodes
Specialty:
All
All AI for Oncology Biosimilars Brain Cancer Breast Cancer CAR T-Cell Therapy Disparities in Cancer Care Gastrointestinal Cancer Genitourinary Cancers Global Oncology Graft-vs-Host Disease Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care
EP. 1: Recent Updates in PARP Inhibitor Indications for Ovarian Cancer By Bradley J. Monk, MD, FACS, FACOG, Robert L. Coleman, MD, FACOG, FACS, Shannon N. Westin, MD, MPH, FACOG, Michael J Birrer, MD, PhD Dr Robert Coleman reviews data from the ARIEL-4 trial on rucaparib in recurrent ovarian cancer, sparking a discussion on PARP inhibitor use.
EP. 2: PARP Inhibitors in Ovarian Cancer: The SOLO-3 Trial By Bradley J. Monk, MD, FACS, FACOG, Robert L. Coleman, MD, FACOG, FACS, Shannon N. Westin, MD, MPH, FACOG, Michael J Birrer, MD, PhD Shannon N. Westin, MD, MPH, FACOG, explains the study design and outcomes of the SOLO-3 trial.
EP. 3: PARP Inhibitors as Frontline Maintenance Therapy in Ovarian Cancer By Bradley J. Monk, MD, FACS, FACOG, Robert L. Coleman, MD, FACOG, FACS, Shannon N. Westin, MD, MPH, FACOG, Michael J Birrer, MD, PhD Bradley J. Monk, MD, FACOG, FACS, generates a discussion on the use of PARP inhibitors in ovarian cancer treatment.
EP. 4: Olaparib Combinations for Frontline Maintenance Therapy in Ovarian Cancer Treatment: The PAOLA-1 Trial By Bradley J. Monk, MD, FACS, FACOG, Robert L. Coleman, MD, FACOG, FACS, Shannon N. Westin, MD, MPH, FACOG, Michael J Birrer, MD, PhD Dr Michael Birrer reviews data from the PAOLA-1 trial investigating bevacizumab combination therapy for frontline maintenance therapy in advanced ovarian cancer.
EP. 5: Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial By Bradley J. Monk, MD, FACS, FACOG, Robert L. Coleman, MD, FACOG, FACS, Shannon N. Westin, MD, MPH, FACOG, Michael J Birrer, MD, PhD Robert L. Coleman, MD, FACOG, FACS, describes data updates from the PRIMA trial investigating PARP inhibition in HRD-negative ovarian cancer populations.
EP. 6: The Rationale for PARP Inhibition plus IO in Ovarian Cancer By Bradley J. Monk, MD, FACS, FACOG, Robert L. Coleman, MD, FACOG, FACS, Shannon N. Westin, MD, MPH, FACOG, Michael J Birrer, MD, PhD Michael J. Birrer, MD, PhD, explains the reasoning for combining PARP inhibitors with immunotherapy in ovarian cancer treatment, highlighting ongoing trials.
EP. 7: Novel Maintenance Strategies Being Explored in Advanced Ovarian Cancer Treatment By Bradley J. Monk, MD, FACS, FACOG, Robert L. Coleman, MD, FACOG, FACS, Shannon N. Westin, MD, MPH, FACOG, Michael J Birrer, MD, PhD A look at the maintenance treatment strategies for advanced or metastatic ovarian cancer.
EP. 8: PARP Inhibitor Resistance in Ovarian Cancer Treatment By Bradley J. Monk, MD, FACS, FACOG, Robert L. Coleman, MD, FACOG, FACS, Shannon N. Westin, MD, MPH, FACOG, Michael J Birrer, MD, PhD Experts discuss the best approach to treating patients with ovarian cancer who are resistant to PARP inhibitors.
EP. 9: The Rationale for PARP Inhibitor Treatment for HRD-Positive Ovarian Cancer By Bradley J. Monk, MD, FACS, FACOG, Robert L. Coleman, MD, FACOG, FACS, Shannon N. Westin, MD, MPH, FACOG, Michael J Birrer, MD, PhD Dr Shannon Westin shares if and when she could justify withholding a PARP inhibitor from a patient with HRD-positive ovarian cancer.
EP. 10: Antibody-Drug Conjugates in Ovarian Cancer Treatment By Bradley J. Monk, MD, FACS, FACOG, Robert L. Coleman, MD, FACOG, FACS, Shannon N. Westin, MD, MPH, FACOG, Michael J Birrer, MD, PhD Dr Michael Birrer highlights updated data on antibody-drug conjugates in ovarian cancer treatment.
EP. 11: Clinical Trial Data on Antibody-Drug Conjugate Treatment for Ovarian Cancer By Bradley J. Monk, MD, FACS, FACOG, Robert L. Coleman, MD, FACOG, FACS, Shannon N. Westin, MD, MPH, FACOG, Michael J Birrer, MD, PhD Drs Coleman and Westin continue the discussion of antibody-drug conjugates for treatment of ovarian cancer.
EP. 12: Investigative Therapies in Recurrent Ovarian Cancer By Bradley J. Monk, MD, FACS, FACOG, Robert L. Coleman, MD, FACOG, FACS, Shannon N. Westin, MD, MPH, FACOG, Michael J Birrer, MD, PhD A key opinion leader reviews data on novel investigational agents for recurrent ovarian cancer.
EP. 13: Treatment of Rare Tumors in Ovarian Cancer By Bradley J. Monk, MD, FACS, FACOG, Robert L. Coleman, MD, FACOG, FACS, Shannon N. Westin, MD, MPH, FACOG, Michael J Birrer, MD, PhD Dr Shannon Westin explains the data on treatment of rare tumors in ovarian cancer and why biomarker testing is essential.
EP. 14: Key Data Highlights in Ovarian Cancer By Bradley J. Monk, MD, FACS, FACOG, Robert L. Coleman, MD, FACOG, FACS, Shannon N. Westin, MD, MPH, FACOG, Michael J Birrer, MD, PhD The panel closes their discussion by highlighting their favorite news or update from recent conferences, including ESMO 2022.
